Can Presumptive Anthelminthic Treatment Delay the Progression of HIV in ART-naïve Patients in Rural Africa?
Can Anthelminthic Treatment Delay the Progression of HIV? Randomised Open-label Trial Testing Presumptive Anthelminthic Treatment on Progression of HIV in ART-naïve HIV-positive Patients in a Rural African Setting With Presumed High Prevalence of Helminth Infections.
Sponsor: Ifakara Health Research and Development Centre
Terminated
Terminated prematurely due to recruitment difficulties. Expansion to more study sites not planned.
This NA trial investigates HIV Infections and Helminthiasis and is currently terminated or withdrawn. Ifakara Health Research and Development Centre leads this study, which shows 11 recorded versions since 2009 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Jul 2023 — Jul 2024 [monthly]
Terminated NA
-
Dec 2021 — Jul 2023 [monthly]
Terminated NA
-
Jan 2021 — Dec 2021 [monthly]
Terminated NA
▶ Show 6 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Terminated NA
-
Jan 2019 — Nov 2020 [monthly]
Terminated NA
-
Jun 2018 — Jan 2019 [monthly]
Terminated NA
-
May 2018 — Jun 2018 [monthly]
Terminated NA
-
Aug 2017 — May 2018 [monthly]
Terminated NA
-
Jan 2017 — Aug 2017 [monthly]
Terminated NA
First recorded
Jan 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ifakara Health Research and Development Centre
- Insel Gruppe AG, University Hospital Bern
- Merck KGaA, Darmstadt, Germany
- Swiss Tropical & Public Health Institute
For direct contact, visit the study record on ClinicalTrials.gov .